HC Wainwright reiterated their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research report report published on Wednesday,Benzinga reports. The brokerage currently ...
Investment analysts at Lifesci Capital boosted their Q1 2025 earnings per share estimates for shares of Corbus ...
Zacks Investment Research on MSN1d
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should KnowCorbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
Corbus Pharmaceuticals Holdings Inc. closed 89.03% below its 52-week high of $61.90, which the company reached on July 31st.
The stock's fall snapped a two-day winning streak.
Oppenheimer analyst Jeff Jones reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of ...
RBC Capital analyst Brian Abrahams maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) yesterday and set a price target ...
CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback